CNS Response, Inc.
HCID Member | Medical Devices & Tech
2755 Bristol St.
Cosa Mesa, CA 92626-5985 USA
phone: 714-545-3288
fax: 866-294-2611
Symbol CNSO
Exchange .OB
Founded 2000
Employees 20
www.cnsresponse.com
Research Sector Medical Devices & Tech
Summary Description
rEEG technology for the assessment of neurophysiological abnormalities and determination of psychiatric treatment
Management
Leonard Brandt, Chief Executive Officer
George Carpenter, President
Daniel Hoffman, M.D., Chief Medical Officer
Brian MacDonald, Chief Engineer
Mark Desrosiers, SVP, Commercial Operations
Ken Graap, Director, Network Services
Barry Kass, Clinical Liaison


Board of Directors
Len Brandt
Henry Harbin, M.D.
David Jones
Jerry Vacarro, M.D.

Scientific Advisory Board
William E. Bunney, Jr., M.D.
Senior Associate Dean for Research
School of Medicine, University of California, Irvine

Maurizio Fava, M.D.
Vice Chair, Department of Psychiatry, Massuchusetts General Hospital
Professor of Psychiatry, Harvard Medical School

Alan Schatzberg, M.D.
Faculty Chairman
Stanford School of Medicine, Department of Psychiatry
2008 APA President

Max Schneider, M.D.
Past President of the American Society of Addiction Medicine (ASAM)
Past Chair and Current Member of the Board of Directors of the National Council on Alcoholism and Drug Dependence (NCADD)

Stephen Suffin, M.D.
Corporate Clinical Pathologist
Chief Laboratory Officer, Quest Diagnostics
Co-Founder of CNS Response
Ownership
Financials Mkt Cap :25


* numbers in thousands

 
Keywords
depression, diagnostics, neurology, psychiatry, mental, reeg, behavioral disorders, anorexia, bulimia, drug addiction, addictions

Comment | Printable Version | Nov. 01, 2008
If you work for CNS Response, Inc. and want to update this profile, click here

Description
CNS Response is the first company to discover the basis for matching mental and addiction patient physiology to treatment outcomes (a biomarker system), thereby altering the treatment of neuropsychiatric illness.
Products / Services
Referenced-EEG (rEEG) enhances a physician's ability to manage psychiatric medications in patients from 6 to 90 years of age. It has been proven useful in research and clinical use in patients with a broad range of diagnoses, including mood, anxiety, eating, obsessive-compulsive, traumatic, personality, and addictive disorders. rEEG has proven particularly useful in what are called treatment-refractory patients - patients who have undergone numerous medication treatment trials with unsatisfactory results.
Technology / Differentiation
Medical treatment of mental disorders differs fundamentally from the treatment of all other health disturbances in that psychiatrists or addiction specialists have no objective physiologic brain measurement systems available to guide treatment of mental or addictive illness. rEEG uses digital electroencephalography in conjunction with a normative database and a proprietary clinical database to identify abnormal patient physiology.
Market / Customers
The psychiatric treatment market accounts for 7.4% of healthcare spending, second only to heart disease. In the U.S., depression affects more than 18 million people; physicians write 11 million prescriptions for depression per month. Other central nervous system disorders include anxiety, addiction, eating disorders and schizophrenia.
Status
CNS Response has developed the Referenced-EEG (rEEG) patented technology that utilizes common electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical database to identify abnormal patient physiology. The treatment has 80% effectiveness in retrospective and prospective studies, and in managed care, outpatient psychiatric and residential substance abuse clinical settings.


2008-11-22-4455